AI Article Synopsis
- The study examined the role of soluble E-cadherin (sE-cad) levels in patients with newly diagnosed non-small cell lung cancer (NSCLC) compared to healthy individuals.
- There was a significant increase in sE-cad levels in NSCLC patients, which was linked to the development of distant metastases and poorer patient outcomes.
- While the findings indicate that sE-cad could be a potential prognostic biomarker for NSCLC, it was not proven to be an independent factor for survival in this analysis.
Article Abstract
Aim: Aberrant expression of the epithelial transmembrane adhesion molecule E-cadherin (E-cad) has been associated with many human malignancies. In the present study the clinical significance of serum levels of soluble E-cadherin (sE-cad) in newly diagnosed patients with non small cell lung cancer (NSCLC) was investigated.
Material And Methods: An enzyme linked immunospecific assay (ELISA) to determine the circulating levels of sE-cad in 20 newly diagnosed patients with NSCLC as well as in 29 healthy volunteers (control group) was used.
Results: NSCLC patients exerted increased circulating levels of sE-cad compared with individuals of the control group (p < 0.001). An association was also detected between serum sE-cad levels and the development of distant metastases. On the contrary, no statistically significant correlation could be established with histological type, gender and smoking habits. Patients with increased sE-cad levels at diagnosis had worser outcome, although multivariate analysis failed to demonstrate that sE-cad levels represent an independent prognostic factor of survival.
Conclusion: Our data suggest that E-cad plays a role in the pathogenesis of NSCLC. sE-cad levels may be further studied as a potential prognostic biomarker.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical utility of quantitative ultrasonography parameters combined with serum cancer antigen 15‑3, human epidermal growth factor receptor 2 and soluble E‑cadherin in diagnosing mass‑type breast cancer.
Oncol Lett
March 2025
Department of Imaging, The Affiliated Hospital of Beihua University, Jilin, Jilin 132011, P.R. China.
Contrast-enhanced ultrasonography (CEUS), a newly developed imaging technique, holds certain value in differentiating benign from malignant tumors. Additionally, serum tumor markers also exhibit significant clinical importance in the diagnosis and monitoring of malignant tumors. Reports have indicated abnormal expression of HER-2, CA153 and sE-cad in breast cancer.
View Article and Find Full Text PDF[Changes in Serum , PCⅢ, SE-CAD Levels in AML Patients after Chemotherapy with DCAG Regimen and Their Relationship with Prognosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2024
Department of Clinical Laboratory, Guangyuan Central Hospital, Guangyuan 628400, Sichuan Province, China.E-mail:
Objective: To investigate the changes in serum homeobox A9 ( ), soluble E-cadherin (SE-CAD) and type Ⅲ procollagen (PCⅢ) levels in acute myeloid leukemia (AML) patients after chemotherapy with DCAG regimen and their relationship with prognosis.
Methods: The clinical data of 80 patients with relapsed/refractory AML diagnosed and treated in our hospital from March 2018 to December 2021 were retrospectively analyzed. According to different treatment regimen, the patients were divided into DCAG group (=40) and CAG group (=40).
Regulation of Soluble E-Cadherin Signaling in Non-Small-Cell Lung Cancer Cells by Nicotine, BDNF, and β-Adrenergic Receptor Ligands.
Biomedicines
September 2023
Chemistry Department, Eastern Michigan University, Ypsilanti, MI 48197, USA.
The ectodomain of the transmembrane protein E-cadherin can be cleaved and released in a soluble form referred to as soluble E-cadherin, or sE-cad, accounting for decreased E-cadherin levels at the cell surface. Among the proteases implicated in this cleavage are matrix metalloproteases (MMP), including MMP9. Opposite functions have been reported for full-length E-cadherin and sE-cad.
View Article and Find Full Text PDFSoluble E-cadherin: A marker of genital epithelial disruption.
Am J Reprod Immunol
March 2023
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Problem: The genital epithelial barrier is a crucial first line of defence against HIV, and epithelial disruption may enhance HIV susceptibility. Assessment of genital epithelial integrity requires biopsies, but their collection is not practical in many research settings. A validated biomarker of genital epithelial barrier integrity would therefore be useful.
View Article and Find Full Text PDFThe Potential Role of CDH1 as an Oncogene Combined With Related miRNAs and Their Diagnostic Value in Breast Cancer.
Front Endocrinol (Lausanne)
July 2022
Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan, China.
Background: Breast cancer (BC) is the leading cause of cancer-related mortality in females and the most common malignancy with high morbidity worldwide. It is imperative to develop new biomarkers and therapeutic targets for early diagnosis and effective treatment in BC.
Methods: We revealed the oncogene function of cadherin 1 (CDH1) bioinformatic analysis in BC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!